Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study
Authors Sun XS, Liang YJ, Li XY, Liu SL, Chen QY, Tang LQ, Mai HQ
Received 10 May 2019
Accepted for publication 1 September 2019
Published 10 September 2019 Volume 2019:13 Pages 3207—3216
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Tin Wui Wong
Xue-Song Sun,1–3,* Yu-Jing Liang,1–3,* Xiao-Yun Li,1–3,* Sai-Lan Liu,1–3 Qiu-Yan Chen,1–3 Lin-Quan Tang,1–3 Hai-Qiang Mai1–3
1Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Guangzhou, People’s Republic of China; 2Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangzhou, People’s Republic of China; 3Department of Nasopharyngeal Carcinoma, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin-Quan Tang;Hai-Qiang Mai
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, People’s Republic of China
Tel +86 208 734 3643
Fax +86 208 734 3392
Email email@example.com; firstname.lastname@example.org
Objective: We aimed to investigate the efficacy and safety of cetuximab (CTX) or nimotuzumab (NTZ) on the addition of palliative chemotherapy (PCT) in patients with de novo metastatic nasopharyngeal carcinoma (NPC).
Materials and methods: From 2007 to 2016, 451 eligible patients with de novo metastatic NPC were enrolled in the study. With propensity score matching technique, we created a well-balanced cohort by matching patients who received CTX/NTZ plus PCT (62 patients) with those receiving PCT alone (248 patients) in a ratio of 1:4. The primary endpoint was overall survival (OS). All potential prognostic factors were involved in the multivariate analysis with the Cox regression hazards model. Kaplan–Meier curves were used to compare the survival status, and log-rank test to measure the significance.
Results: The median follow-up time was 27.7 months (range, 1–126 months). No significant difference in survival was observed between the CTX/NTZ plus PCT group and PCT group. (3-year OS: 63.0% vs 58.1%; P=0.485). The administration of CTX/NTZ was not found to be an independent prognostic factor in multivariate analysis. With regard to toxicity, the development of a G3-4 skin reaction and mucositis was more common in patients receiving CTX plus PCT. Interaction effects analysis did not show any significant interaction effects on OS between the treatment regimen and prognostic factors (P>0.05).
Conclusion: The efficacy of CTX/NTZ and PCT is comparable to single PCT treatment in terms of survival outcomes among de novo metastatic NPC patients. Moreover, the application of CTX exacerbated skin reactions and mucositis.
Keywords: targeted drug, chemotherapy, treatment, nasopharyngeal carcinoma and overall survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]